Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
复制标题
DOI：
10.1186/s13045-018-0568-6
复制
发表时间：
2018-02-13
影响因子：
28.5
通讯作者：
Zhao Q
中科院分区：
文献类型：
--
作者：
Li J;Li W;Huang K;Zhang Y;Kupfer G;Zhao Q
最近，美国食品和药物管理局(FDA)批准了第一个嵌合抗原受体T细胞(CAR-T)疗法，用于治疗CD19阳性的B细胞急性淋巴细胞白血病。虽然CAR-T在治疗血液系统恶性肿瘤方面取得了显著的成功，但它是否能同样程度地惠及实体瘤患者仍不确定。尽管数百项临床试验正在探索各种肿瘤相关抗原(TAA)，但尚未发现具有CD19类似特性的此类抗原用于实体瘤CAR-T免疫治疗。T细胞转运效率低、肿瘤微环境免疫抑制、抗原识别特异性差、缺乏安全控制是目前实体瘤CAR-T治疗的主要障碍。在这里，我们回顾了实体瘤CAR-T的临床试验，重点介绍了已发表结果的研究。我们进一步讨论了CAR-T在实体瘤治疗方面所面临的挑战，并提出了提高CAR-T作为有前途的免疫治疗的疗效的潜在策略。
Recently, the US Food and Drug Administration (FDA) approved the first chimeric antigen receptor T cell (CAR-T) therapy for the treatment CD19-positive B cell acute lymphoblastic leukemia. While CAR-T has achieved remarkable success in the treatment of hematopoietic malignancies, whether it can benefit solid tumor patients to the same extent is still uncertain. Even though hundreds of clinical trials are undergoing exploring a variety of tumor-associated antigens (TAA), no such antigen with comparable properties like CD19 has yet been identified regarding solid tumors CAR-T immunotherapy. Inefficient T cell trafficking, immunosuppressive tumor microenvironment, suboptimal antigen recognition specificity, and lack of safety control are currently considered as the main obstacles in solid tumor CAR-T therapy. Here, we reviewed the solid tumor CAR-T clinical trials, emphasizing the studies with published results. We further discussed the challenges that CAR-T is facing for solid tumor treatment and proposed potential strategies to improve the efficacy of CAR-T as promising immunotherapy.
登录
查看更多内容
影响因子：
--
作者：
Ahmad ZA;Yeap SK;Ali AM;Ho WY;Alitheen NB;Hamid M
通讯作者：
Hamid M
影响因子：
45.3
作者：
Ahmed, Nabil;Brawley, Vita S.;Gottschalk, Stephen
通讯作者：
Gottschalk, Stephen
淋巴瘤中HVEM肿瘤抑制剂的丧失和修饰的CAR-T细胞恢复。
影响因子：
64.5
作者：
Boice M;Salloum D;Mourcin F;Sanghvi V;Amin R;Oricchio E;Jiang M;Mottok A;Denis-Lagache N;Ciriello G;Tam W;Teruya-Feldstein J;de Stanchina E;Chan WC;Malek SN;Ennishi D;Brentjens RJ;Gascoyne RD;Cogné M;Tarte K;Wendel HG
通讯作者：
Wendel HG
DOI：
10.1158/1078-0432.ccr-15-0428
发表时间：
2015-09-15
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
Brown CE;Badie B;Barish ME;Weng L;Ostberg JR;Chang WC;Naranjo A;Starr R;Wagner J;Wright C;Zhai Y;Bading JR;Ressler JA;Portnow J;D'Apuzzo M;Forman SJ;Jensen MC
通讯作者：
Jensen MC
影响因子：
4.2
作者：
Abate-Daga, Daniel;Lagisetty, Kiran H.;Morgan, Richard A.
通讯作者：
Morgan, Richard A.